AI drug breakthrough: Google DeepMind spinoff Isomorphic Labs begins human trials
'It's going to be a very exciting moment as we go into clinical trials,' Isomorphic Labs President says
Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, is set to begin human trials of drugs designed by its Nobel Prize-winning AI technology.
No one can deny the role of Google DeepMind in revolutionizing drug discovery. For instance, DeepMind's AlphaFold has fundamentally transformed the scientists’ understanding of protein structures.
Now, the platform faces its next major challenge: proving it can transition from mapping biology to actively designing safe, effective new medicines.
Talking to the Wired, the Isomorphic Labs President, Max Jaderberg, said, “We're gearing up to go into the clinic. It's going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules.”
However, Jaderberg did not stipulate the definite timeline, but it’s later than the company had planned to start human studies. But, the DeepMind CEO Demis Hassabis said, by the end of 2025, the company would enter clinical trials of AI-designed drugs.
Founded in 2021, Isomorphic Labs, a spinoff from Alphabet’s AI research subsidiary, Google DeepMind. The company deploys AlphaFold for drug discovery.
Isomorphic Labs recently introduced IsoDDE (Iso Drug Design Engine), a tool claimed to be twice as accurate as AlphaFold 3, a tool released in 2024.
The company also collaborated with pharmaceutical giants Eli Lilly and Novartis. It is also developing an internal pipeline of medicines focused on immunology and oncology.
These AI-designed molecules are engineered to be more potent, meaning patients can take lower doses with fewer side effects and off-target complications.
“The exciting thing about the molecules that we're designing is because we have so much more of an understanding about how these molecules work, we've engineered them to be very, very potent,” Jaderberg said.
The company is also developing a clinical development team with the mission of solving all diseases.
Jaderberg said, “It's a crazy mission. But we really mean it. We say it with a straight face, because we believe this should be possible.”
-
How Trump’s ‘forever chemicals’ rollback could impact drinking water across America
-
Study reveals watermelon may boost heart health and diet quality
-
WHO declares Ebola outbreak emergency in DR Congo
-
Plastic surgeons see rise in AI-generated beauty requests
-
Vitamin B2 may help cancer cells survive, scientists reveals dark side
-
Ebola returns to DR Congo, Africa CDC confirms
-
Hantavirus outbreak: Could it be new pandemic threat like COVID? Experts weigh in
-
Meningitis leaves one dead, others critically ill; Know how it spreads
-
PCOS renamed PMOS: What new diagnosis means for millions of women’s health
-
Endometriosis linked to small increase in birth defect risk in Canadian study
-
Health Canada issues safety warning over baby self-feeding products sold on Amazon
-
Do psychopaths and others have same brain structure? Scientists reveal shocking details
